QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)

Insider Selling: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director Sells 4,904 Shares of Stock

Treace Medical Concepts, Inc. (NASDAQ:TMCI - Get Rating) Director Thomas E. Timbie sold 4,904 shares of Treace Medical Concepts stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $19.04, for a total transaction of $93,372.16. Following the completion of the transaction, the director now directly owns 1,499,069 shares in the company, valued at approximately $28,542,273.76. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Treace Medical Concepts Trading Down 0.1 %

Shares of TMCI traded down $0.01 during midday trading on Friday, hitting $19.57. The stock had a trading volume of 259,024 shares, compared to its average volume of 205,917. Treace Medical Concepts, Inc. has a fifty-two week low of $12.48 and a fifty-two week high of $31.02. The business has a 50-day simple moving average of $15.95 and a two-hundred day simple moving average of $17.76. The firm has a market cap of $1.08 billion, a P/E ratio of -39.14 and a beta of 0.06. The company has a current ratio of 8.28, a quick ratio of 7.56 and a debt-to-equity ratio of 0.34.

Treace Medical Concepts (NASDAQ:TMCI - Get Rating) last announced its earnings results on Thursday, May 5th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. Treace Medical Concepts had a negative net margin of 25.92% and a negative return on equity of 28.57%. The company had revenue of $29.05 million during the quarter, compared to analysts' expectations of $26.18 million. During the same period last year, the company posted ($0.07) earnings per share. As a group, equities analysts forecast that Treace Medical Concepts, Inc. will post -0.64 EPS for the current year.

Wall Street Analysts Forecast Growth


Several equities analysts have recently issued reports on TMCI shares. BTIG Research started coverage on shares of Treace Medical Concepts in a research note on Thursday, May 12th. They issued a "buy" rating and a $22.00 price objective on the stock. Stifel Nicolaus lowered their price objective on shares of Treace Medical Concepts from $32.00 to $21.00 in a research note on Monday, July 18th. Finally, Morgan Stanley decreased their target price on shares of Treace Medical Concepts from $26.00 to $22.00 and set an "overweight" rating for the company in a report on Friday, July 15th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. CWM LLC acquired a new stake in shares of Treace Medical Concepts during the second quarter worth approximately $28,000. Amalgamated Bank acquired a new stake in shares of Treace Medical Concepts during the first quarter worth approximately $93,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Treace Medical Concepts during the first quarter worth approximately $189,000. New York State Common Retirement Fund boosted its holdings in shares of Treace Medical Concepts by 30.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,396 shares of the company's stock worth $231,000 after purchasing an additional 2,880 shares during the period. Finally, FWL Investment Management LLC acquired a new stake in shares of Treace Medical Concepts during the fourth quarter worth approximately $321,000. 34.78% of the stock is currently owned by institutional investors and hedge funds.

Treace Medical Concepts Company Profile

(Get Rating)

Treace Medical Concepts, Inc, an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.

Featured Articles

Insider Buying and Selling by Quarter for Treace Medical Concepts (NASDAQ:TMCI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Treace Medical Concepts right now?

Before you consider Treace Medical Concepts, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.

While Treace Medical Concepts currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastInvesting in What You Know Has Changed

What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.